Key statistics
On Tuesday, Lipocine Inc (LPCN:NAQ) closed at 8.81, -28.78% below its 52-week high of 12.37, set on Jan 15, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.79 |
|---|---|
| High | 9.32 |
| Low | 8.52 |
| Bid | 5.52 |
| Offer | 9.68 |
| Previous close | 8.89 |
| Average volume | 89.18k |
|---|---|
| Shares outstanding | 5.55m |
| Free float | 5.39m |
| P/E (TTM) | -- |
| Market cap | 48.91m USD |
| EPS (TTM) | -1.04 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
Press releases
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
- Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
